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Abstract  
Background—Lecithin:cholesterol acyltransferase (LCAT) is the sole enzyme that esterifies 
cholesterol in plasma. Its role in the supposed protection from atherogenesis remains unclear 
since mutations in LCAT causing Fish-Eye Disease (FED) or Familial LCAT Deficiency (FLD) 
have been reported to be associated with more or instead less carotid atherosclerosis, 
respectively. This discrepancy may be associated with the loss of cholesterol esterification on 
only apolipoprotein (apo) A-I (FED) or on both apoA-I and apoB-containing lipoproteins (FLD), 
an aspect that has thus far not been investigated. 
Methods—Seventy-four heterozygotes for LCAT mutations recruited from Italy and the 
Netherlands were assigned to FLD (n=33) or FED (n=41) groups and compared to 280 controls. 
Subclinical atherosclerosis was assessed using carotid intima-media thickness (IMT). 
Results—Compared to controls, total cholesterol was lower by 16% (-32.9 mg/dL) and 7% (-
14.9 mg/dL), and HDL cholesterol was lower by 29% (-16.7 mg/dL) and 36% (-20.7 mg/dL) in 
the FLD and FED groups, respectively. FLD subjects displayed a significant 18% lower LDL 
cholesterol compared with FED (101.9±35.0 vs 123.6±47.4 mg/dL, P=0.047) and controls 
(122.6±35.0 mg/dL, P=0.003). Remarkably, all three IMT parameters were lower in FLD 
compared to FED and controls (accounting for age, sex, BMI, smoking, hypertension, family 
history of cardiovascular disease and plasma lipids). After additional correction for nationality 
and ultrasonographic methods, average and maximum IMT remained significantly lower when 
comparing FLD to FED (0.59mm vs 0.73mm, P=0.003, and 0.87mm vs 1.24mm, P<0.001, 
respectively). By contrast, the common carotid IMT (corrected for age, sex, BMI, smoking, 
hypertension, family history of cardiovascular disease, and plasma lipids) was higher in FED 
compared to controls (0.69mm versus 0.65mm, P=0.05), but this significance was lost after 
adjustment for nationality and ultrasonographic machine. 
Conclusions—In this head-to-head comparison, FLD and FED mutations were shown to be 
associated with decreased and increased atherosclerosis, respectively. We propose that this 
discrepancy is related to the capacity of LCAT to generate cholesterol esters on apoB-containing 
lipoproteins. While this capacity is lost in FLD, it is unaffected in FED. These results are 
important when considering LCAT as a target to decrease atherosclerosis. 
Key Words: LCAT deficiency; carotid IMT; atherosclerosis 
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Clinical Perspective 
 
What is new?  
? Half-century of LCAT research has established its important function in HDL metabolism; 
however, the role of this enzyme in human atherogenesis still remains controversial.  
? In this study, we tested the hypothesis that genetic mutations causing complete LCAT 
deficiency (FLD) or partial LCAT deficiency (FED) are differentially associated with carotid 
atherosclerosis in carriers of LCAT mutations.  
? Using carotid intima-media thickness (IMT) as a measure of atherosclerosis, we demonstrate 
that carriers of LCAT mutations leading to FLD exhibit less carotid atherosclerosis, indicating 
a reduced risk of cardiovascular disease.  
? By contrast, carriers of LCAT mutations leading to FED show marginally more 
atherosclerosis. 
? The association of mutations in LCAT with subclinical atherosclerosis appears to be related to 
the capacity of LCAT to esterify cholesterol on apoB-containing lipoproteins since the 
abnormal LCAT present in FED is only active on this class of lipoproteins. 
 
What are the clinical implications? 
? These findings bear relevance for pharmaceutical strategies that target LCAT such as the 
recombinant enzyme for replacement therapy and, more importantly, small molecules aimed 
at increasing LCAT activity which previously has been thought to decrease risk of 
atherosclerosis.  
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Introduction 
Genetic LCAT deficiency is a rare autosomal recessive disorder due to mutations in the LCAT 
gene.1 Importantly, these mutations translate into two different clinical presentations known as 
Familial LCAT Deficiency (FLD; OMIM# 245900), and Fish-Eye Disease (FED; OMIM# 
136120). Compound heterozygosity or homozygosity for mutations causing either FLD or FED 
is characterized by near absent HDL cholesterol.2 Furthermore, heterozygosity for mutations in 
LCAT causes up to a 40% decrease in HDL cholesterol.3, 4 In FLD cases, the lack of LCAT 
catalytic activity is complete thereby affecting the ability of the enzyme to esterify free 
cholesterol on both HDL and LDL. As a consequence, cholesteryl esters (CE) are virtually 
absent in plasma. By contrast, mutations causing FED result in a loss of the capacity of LCAT to 
esterify cholesterol only in HDL and yet retains the ability to esterify cholesterol on 
apolipoprotein (apo)B-containing lipoproteins (VLDL and LDL). As a result, plasma CE are 
mainly associated with LDL particles.2 Clinical manifestations of a loss of LCAT activity are 
only observed in subjects who are homozygotes or compound heterozygotes for LCAT 
mutations.2 Corneal opacity is the most common feature in FLD and FED cases whereas 
anaemia, proteinuria and renal disease are clinical features in only FLD cases.2 Of note, 
glomerulosclerosis is the major cause of morbidity and mortality in FLD cases as it ultimately 
leads to renal failure.2 The pathogenesis of renal disease in FLD is not completely understood, 
but it is likely related to the accumulation of abnormal lipoproteins including large molecular 
weight LDL particles5 and lipoprotein X (LpX).6 
 Epidemiologic studies have clearly established the inverse association between HDL 
cholesterol and risk of cardiovascular disease (CVD).7 Thus, individuals suffering from near 
complete loss of HDL or even half normal HDL are hypothesized to be at very high CVD risk. In 
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a first study by Ayyobi et al., however, 2 homozygotes and 7 heterozygotes from a large 
Canadian kindred with FLD have been followed for 25 years, during which time no vascular 
events were reported in any of the carriers aged up to 70 years.8 Interestingly, the homozygotes 
had only minimally greater carotid intima media thickness (IMT) and no plaques, while some 
IMT abnormalities were observed in four out of seven heterozygotes.8 In a much larger carotid 
IMT study in the Netherlands, measurements were performed in 9 carriers of two mutant LCAT 
alleles, 47 carriers of one mutant LCAT allele and 58 age and gender-matched family controls. 
All individuals belonged to 5 families of whom the index cases all presented with FED.3 
Heterozygous carriers were reported to have significantly greater carotid IMT compared to 
family controls and two had premature cardiovascular events.3 This population was later on re-
assessed by measuring carotid artery wall thickness by 3.0-T carotid magnetic resonance 
imaging showing that these carriers of LCAT mutations had thicker carotid artery walls and 32% 
more plaque component compared to family controls.9 In sharp contrast, a study in Italian 
families in which the majority of the index cases suffered from FLD showed significantly 
smaller carotid IMT in carriers of LCAT mutations compared to age-gender matched controls, 
with a convincing distinct gene-dose effect.4 
 These contrasting prior findings suggest the question: Does the development of 
preclinical atherosclerosis follow a different course in partial LCAT deficiency (FED) compared 
to complete LCAT deficiency (FLD)? It is critical that this question is addressed since the 
answer will influence the effectiveness as well as safety of pharmaceutical strategies that target 
LCAT. These include both enzyme replacement therapy to treat FLD10 but, more importantly, 
small molecules aimed at increasing LCAT activity to decrease risk of atherosclerosis.11 In this 
light, we have tested the hypothesis that FLD and FED are two disease entities with different 
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associations with atherosclerosis. Our results highlight remarkable discrepancies between the 
two LCAT disease entities in a first head to head comparison. 
 
Methods 
The raw data that support the findings of this study are available from the corresponding authors 
upon reasonable request. 
Subjects 
A total of 375 subjects were included in this study, 168 recruited from Italy and 207 from the 
Netherlands. Among the 168 Italian subjects, 55 were carriers of LCAT mutations in previously 
identified families,12, 13 while 113 were controls recruited among blood donors. From 207 Dutch 
subjects, 40 were carriers of LCAT mutations and 167 were controls (comprising 137 family 
members9 and 30 age-gender matched healthy controls).  
 A total of 16 individuals were carriers of two mutant LCAT alleles (homozygotes or 
compound heterozygotes), 11 of whom were biochemically12 diagnosed with FLD, all Italians, 
while 5 subjects (4 Italians and 1 Dutch) were classified as FED. Seventy-nine individuals 
carried one mutant LCAT allele and were assigned to either the FLD or FED group on the basis 
of all available data. Specifically, heterozygotes for mutations known to cause FLD or FED in 
homozygotes were assigned FLD or FED, respectively. In case such information was not present 
(in families in which the index cases were compound heterozygotes), we used biochemical 
information that was obtained through in vitro characterization of the respective mutants.4  In 
case such information was not available, the subjects were excluded from our study which was 
the case in 5 individuals. Following, of the 74 remaining heterozygotes, 33 (26 Italians and 7 
Dutch) and 41 (9 Italians and 32 Dutch) subjects were classified as FLD and FED, respectively. 
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A detailed and complete overview of the LCAT mutations and associated biochemical phenotype 
can be found in the supplemental material, including mutation carriers that were not included 
because no appropriate data was present to assign them to either the FLD or FED group 
(Supplemental Table I). 
 Personal and family history of CVD and cardiovascular risk factors were surveyed by 
questionnaires. Personal and family history of CVD was not specifically used to include or 
exclude subjects for this study. Biometrics including blood pressure were recorded and fasting 
blood samples were collected. Hypertension was defined as a blood pressure over 140/90 mm Hg 
or use of antihypertensive medication. None of the participants was taking medication known to 
affect plasma lipid/lipoprotein levels. All subjects were fully informed about the modalities of 
the study and signed informed consent. All procedures were approved by the institutional Ethic 
Committees. 
Biochemical Analysis 
Plasma total and HDL cholesterol and triglyceride levels were determined with certified 
enzymatic methods. In addition, LDL and non-HDL cholesterol were calculated by the 
Friedewald’s equation and as the difference between total and HDL cholesterol, respectively. In 
the case of triglycerides levels>400 mg/dL (2 carriers and 2 controls), LDL cholesterol was 
assessed using a direct measurement method. 
Carotid Ultrasonography 
Carotid IMT was performed using standardized techniques for all carriers of LCAT gene 
mutations and controls. All ultrasonographic scans were performed with the subjects laying in 
the supine position. Right and left carotid artery segments (common carotid artery, bifurcation, 
and internal carotid artery) were identified according to specific landmarks (i.e. flow divider and 
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crest of the bifurcation) and imaged over a length of 10 mm according to a fixed lateral 
transducer angle (lateral). In both the Netherlands and Italy, the affected families are living 
across the two Nations. All carriers and controls who agreed to participate in the Netherlands 
were asked to attend the Department of Vascular Medicine in Amsterdam for IMT assessment, 
whereas all carriers and controls who agreed to participate in Italy were asked to attend the Lipid 
Clinic of the Center E. Grossi Paoletti in Milan. In Italy, when carriers could not travel to Milan, 
the sonographer moved to the family’s site. 
 In the Netherlands, an Acuson 128XP/10v equipped with a 7.0-MHz linear-array 
transducer was used to obtain B-mode ultrasound images of carotid arteries by two blinded 
sonographers. In Italy, ultrasound scanning was also performed by two blinded sonographers by 
using an ESAOTE TECHNOS machine, equipped with a multi-frequency probe of 8.5 MHz. 
When one of the two sonographers moved to the family’s site around the country, ultrasound 
scanning was performed by using a portable device (Logiq E compact ultrasound portable 
system; GE) equipped with a 5.0-13.0 MHz linear array transducer. In the Netherlands images 
were saved as JPEG image files, whereas in Italy the whole ultrasonographic scan was recorded 
on sVHS videotapes from three transducer angles (anterior, lateral and posterior). In order to be 
congruent with Dutch ultrasonographic protocol, only images from the lateral angle were 
considered. All IMT measurements were centralized in Milan and performed by a single expert 
reader blinded for the genotype of the subjects, using dedicated software (M’Ath, Metris SRL 
France) that allows the semi-automatic edge detection of the echogenic lines of the intima-media 
complex. Whenever possible, carotid images were measured in at least 3 different frames. 
Measurements of left and right common carotids were averaged to calculate the mean common 
carotid IMT. 
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 Measurements of the three segments (common carotid artery, bifurcation, and the internal 
carotid artery) of left and right carotids were averaged to calculate the mean IMT (Average 
IMT); the highest IMT value among the three segments of the two carotids was defined as the 
Maximum IMT.  
Statistical Analysis 
Data were summarized as mean±SD or as mean and 95% confidence interval (CI) for normally 
distributed variables, with median and inter-quartile range (IQR) for non-normally distributed 
variables and with n (%) for categorical variables. Carotid IMT variables were log-transformed 
before multivariable analysis and were presented as geometric means and 95% CI. Unadjusted 
pairwise comparisons between groups were performed by Wilcoxon rank-sum test, chi-square 
test, or Fisher exact test, as indicated. Multivariable analysis was performed by ANCOVA using 
three different models: model 1, adjusted for age and sex; model 2, as model 1 with additional 
adjustment for BMI, smoking, hypertension, family history of cardiovascular disease, total 
cholesterol, HDL cholesterol and triglycerides; model 3, as model 2 with further adjustments for 
nation and ultrasonographic machine. P-values below 0.05 were considered as significant, except 
when appropriate Bonferroni correction was applied. All tests were two-sided and were 
performed by SAS v. 9.4 (Sas Institute Inc., Cary, NC, USA). 
 
Results 
Demographic Characteristics and Lipid Levels 
Individuals from the previously reported Italian and Dutch families with mutations in LCAT 
were combined and analysed following identical methods. For the current analysis, we excluded 
homozygotes and compound heterozygotes to account for possible referral bias as these patients 
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may have been initially studied because of cardiovascular complications. The final cohort 
includes 74 proven heterozygous carriers of LCAT gene mutations (33 FLD and 41 FED 
subjects) and 280 controls. Table 1 summarizes the demographic, lifestyle and clinical 
characteristics of the subjects included. Statistical comparisons were made as FED vs FLD 
subjects, FED subjects vs controls and FLD subjects vs controls, respectively.  
 Age and gender distribution were very similar amongst all 3 study groups, while also 
BMI and hypertension were not significantly different between all groups. In addition, the FED 
and FLD groups were also similar for smoking status. Personal history of CVD was significantly 
increased in FED compared to controls, while family history of CVD was comparable in the 3 
groups. 
 With respect to lipids, total cholesterol was significantly lower in FLD and FED subjects 
compared to controls (167.5 ± 39.0 vs 200.4 ± 38.5 mg/dL in FLD vs controls, P<0.0001; 185.5 
± 52.5 vs 200.4 ± 38.5 mg/dL in FED vs controls, P=0.03) but there were no statistically 
significant differences in total cholesterol between FLD and FED subjects. FLD subjects 
exhibited a statistically significant 18% (101.9 ± 35.0 vs 123.6 ± 47.4 mg/dL) lower LDL 
cholesterol compared to FED subjects (P=0.047) and controls (P=0.003). However, LDL 
cholesterol was close to identical when comparing FED subjects with controls (123.6 ± 47.4 vs 
122.6 ± 35.0 mg/dL). Mutations related to FLD or FED were associated with very similar HDL 
cholesterol levels, i.e. 29-36% lower levels compared to controls (41.5 ± 13.2 vs 37.5 ± 14.3 
mg/dL; P<0.0001 for both compared to controls). Non-HDL cholesterol tended to be lower in 
FLD (126.0 ± 40.5 mg/dL) compared to controls (142.2 ± 39.7 mg/dL) and FED subjects (148.0 
± 50.9 mg/dL; P=0.03 and P=0.08, respectively) but, as for LDL cholesterol, it was similar 
between FED subjects and controls (148.0 ± 50.9 vs 142.2 ± 39.7 mg/dL). Finally, fasting 
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plasma triglycerides were significantly higher in FLD (97.0 mg/dL (77.0; 144.0)) and FED 
subjects (100.2 mg/dL (80.8; 145.9)) compared to controls (86.1 mg/dL (59.7; 123.0); P=0.03 
and P=0.02, respectively)), but without differences between the FLD and FED groups. 
Carotid IMT in FLD and FED Mutation Carriers 
Carotid IMT values are presented using three different statistical adjustments: model 1, adjusted 
for age and sex; model 2, same as model 1 with additional adjustment for BMI, smoking, 
hypertension, family history of CVD, total cholesterol, HDL cholesterol and triglycerides; model 
3, same as model 2 with further adjustments for nationality and ultrasonographic machine (Table 
2 and Supplemental Figure I). Overall, FLD subjects exhibited significantly lower IMT 
compared to FED subjects and controls among all the three carotid variables. Specifically, 
common carotid IMT was lower in FLD subjects compared to FED subjects (0.62mm (0.55-
0.69) vs 0.69mm (0.60-0.76), P=0.003). This remained highly statistically significant after 
correction for additional confounders (P<0.001) but was lost after correction also for nation and 
ultrasonographic machine (P=0.091). Common carotid IMT was also significantly lower in FLD 
subjects compared to controls but only after correction for confounders (0.62mm (0.55-0.69) vs 
0.65 (0.55-0.74), P=0.028). In contrast, common carotid IMT was significantly greater in FED 
compared to controls when adjusted for age and gender (0.69mm (0.60-0.76) vs 0.65 (0.55; 
0.74), P=0.005). Upon adjustment for confounders, only a trend to significance was observed 
(P=0.05). When nationality and ultrasonographic machine were taken into account, the 
difference was no longer statistically significant. 
 Average IMT and maximum IMT were profoundly lower in FLD compared to FED 
subjects (0.59mm (0.56-0.79) versus 0.73mm (0.66-0.88), P<0.001, and 0.87mm (0.72-1.30) 
versus 1.24mm (0.95-1.41), P<0.001, respectively). The differences remained statistically 
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significant in all the tested models (Table 2). The same held true when comparing FLD subjects 
and controls (0.59mm (0.56-0.79) versus 0.72mm (0.62-0.83), P<0.001, and 0.87mm (0.72-1.30) 
versus 1.12mm (0.95-1.45), P<0.001, respectively). Regarding average and maximum IMT, FED 
subjects were not different from controls regardless of the statistical model used (Table 2).  
 Upon inclusion of carriers of two mutant LCAT alleles (homozygotes/compound 
heterozygotes, Supplemental Tables II and III) the analysis yielded very similar results 
(Supplemental Table IV).  
 
Discussion  
Despite 50 years of research the role of LCAT in the pathogenesis of atherogenesis remains 
unclear. For example, opposite findings were reported by Hovingh et al.3 and Calabresi et al.4 
who described more and less carotid atherosclerosis in carriers of LCAT gene mutations, 
respectively. It is important to emphasize, however, that Hovingh et al 3 only studied families in 
which the probands were diagnosed with FED while Calabresi et al.4 almost exclusively 
investigated families in which the probands suffered from FLD. In the current study, we have 
carefully discriminated between these two LCAT disease entities on the basis of clinical and 
biochemical features. This was anticipated to be important because LCAT in FED can still 
esterify cholesterol on apoB-containing lipoproteins, while such activity is missing in FLD. 
 After assignment of carriers to FLD or FED groups, we first tested the hypothesis that 
mutations that are associated with FLD or FED have different impacts on the development of 
atherosclerosis. To this end, the previously described Dutch and Italian cohorts were combined 
and used to re-read all carotid IMT images. The study groups and controls had a very similar 
cardiovascular risk profile. The final result shows that mutations causing FLD and FED are 
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indeed differentially associated with subclinical atherosclerosis as determined by IMT. 
Specifically, the FLD group presented with significantly lower IMT compared to controls among 
all three carotid measurements thereby validating previous findings.4 The FED group, however, 
showed a slight increase of only the common carotid IMT compared to controls as reported 
earlier.3 The latter was also in agreement with an additional report on carotid 3.0-T magnetic 
resonance imaging data in the same individuals.9  
 In addressing our hypothesis, the FLD group showed significantly lower IMT values 
across all carotid segments compared to the FED group. To account for possible imbalances 
between Italian and Dutch study sites, all IMT measurements were additionally adjusted for 
nationality and ultrasonographic machine: average and maximum IMT in FLD remained highly 
significantly lower compared to FED which supports the validity of our findings. 
 Since the major cardiovascular risk factors were similar in the FLD and FED groups, the 
identified changes in IMT may be related to differences in plasma lipid fractions resulting from 
different functions in the mutant LCAT proteins. Notably, LDL cholesterol levels were 18% 
lower in FLD compared to FED subjects. In view of the established causal role of LDL 
cholesterol in atherogenesis, this may explain the observed differences in subclinical 
atherosclerosis between the FLD and FED groups when considering the life-long impact of this 
detrimental lipid feature. This was recently highlighted through studies of mutations in another 
gene where a 28% reduction of LDL cholesterol observed in carriers of loss of function 
mutations in PCSK9 were shown to be associated with a remarkable 88% reduction of the risk of 
coronary heart disease.14 Non-HDL cholesterol was also non-significantly reduced in FLD 
compared to FED and controls. Since the reduction of HDL cholesterol levels was similar in both 
the FLD and FED groups compared to controls, this parameter is unlikely to account for 
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differences in IMT between the groups. We cannot exclude, however, that HDL subclasses or 
sizes of LDL and VLDL particles are associated with our observations.15 
 Placing our results in a broader perspective, others have shown that low LCAT activity 
and high pre-β1 HDL concentration are strong positive risk markers for ischemic heart disease 
but independent of HDL cholesterol. 16 We previously showed that LCAT concentration is not 
associated with HDL cholesterol levels or future coronary artery disease17 and also reported that 
a low plasma concentration and activity of LCAT is not associated with carotid atherosclerosis.18 
When considering the relations between LCAT and HDL cholesterol, the above findings are not 
in line with those obtained through families with FLD and FED. This may be explained by 
relatively large reductions of LCAT activity in carriers of LCAT mutations, while the variation 
of LCAT concentrations in other studies was marginal by comparison.17, 18  
 When considering the relation between HDL cholesterol and CVD, the first report on a 
strong inverse association between HDL cholesterol and atherosclerosis7, 19 has been confirmed 
by many other investigators. There is, however, little evidence from studies in humans that this 
relation has a causal basis.20 In considering the role of LCAT in HDL metabolism, a recent 
Mendelian Randomization study showed that low HDL cholesterol associated with common 
LCAT gene variation is not associated with an altered risk of myocardial infarction.21 In line 
with the notion that this relation may not be causal, the current study shows that a marked 
assumedly lifelong 29-36% reduction of HDL cholesterol levels in carriers of LCAT mutations is 
not associated with a markedly greater carotid IMT. In fact, we recapitulate that carriers of FLD 
with very marked hypoalphalipoproteinemia, surprisingly appear significantly protected against 
carotid atherosclerosis. 
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 Taken together, our data show that carriers of FLD mutations exhibit less carotid 
atherosclerosis while FED present with slightly more atherosclerosis. We propose that this 
discrepancy is related to the capacity of LCAT to esterify cholesterol on apoB-containing 
lipoproteins (Figure 1). This is supported by significantly lower LDL cholesterol in carriers of 
FLD mutations compared to carriers of FED mutations. Further studies are, however, warranted 
to improve insight into possible mechanisms underlying the observed differences in the two 
LCAT syndromes. Such studies which we were not able to perform here, may encompass 
measures of lipoprotein composition and size, and cholesterol esterification. In closing, we 
would like to emphasize that our findings may bear consequences for therapeutic approaches to 
increase LCAT activity to fight atherosclerosis. 
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Table 1. Demographic, Clinical, and Lipid/Lipoprotein Data in Heterozygous Carriers of LCAT Gene 
Mutations and Controls 
 
  FLD Carriers FED Carriers Controls 
P value 
(FED vs 
FLD)* 
P value 
(FED vs 
controls)* 
P value 
(FLD vs 
controls)* 
n. 33 41 280   
Italian/Dutch  26/7 9/32 113/167   
Gender (M, %) 18 (54.5%) 27 (65.9%) 152 (54.3%) 0.32 † 0.16 † 0.98 † 
Age (y) 44.8 ± 19.3 44.5 ± 13.8 43.9 ± 13.3 0.76 0.69 0.47 
BMI (kg/m2) 25.0 ± 4.2 25.2 ± 4.6 24.9 ± 3.9 0.74 0.34 0.78 
Smoking status 0.29 ‡ 0.006 ‡ 0.08 ‡ 
Never (n, %) 23 (69.7%) 25 (62.5%) 138 (49.3%)   
Former (n, %) 5 (15.2%) 3 (7.5%) 82 (29.3%)   
Current (n, %) 5 (15.2%) 12 (30.0%) 60 (21.4%)   
Personal history of CVD (n, %) 2 (6.1%) 5 (12.2%) 8 (2.9%) 0.45 ‡ 0.016 † 0.28 ‡ 
Family history of CVD (n, %) 18 (54.5%) 21 (51.2%) 180 (64.3%) 0.77 † 0.11 † 0.27 † 
Hypertension (n, %) 9 (27.3%) 14 (34.1%) 70 (25%) 0.53 † 0.21 † 0.78 † 
Total Cholesterol (mg/dL) 168 ± 39 186 ± 53 200 ± 39 0.12 0.03 <0.0001§ 
LDL Cholesterol (mg/dL) 102 ± 35 124 ± 47 123 ± 35 0.047 0.83 0.003 
HDL Cholesterol (mg/dL) 42 ± 13 38 ± 14 58 ± 16 0.14 <0.0001§ <0.0001§ 
Triglycerides (mg/dL) 97 (77; 144) 100 (81; 146) 86 (60; 123) 0.96 0.02 0.03 
Non-HDL Cholesterol (mg/dL) 126 ± 41 148 ± 51 142 ± 40 0.08 0.60 0.03 
Ratio LDL-C/HDL-C 2.2 (1.9; 3.4) 3.4 (2.2; 4.2) 2.1 (1.6; 2.8) 0.02 <0.0001§ 0.09 
Data are expressed as mean±SD or as geometric mean and 95% CI or as percentage where indicated.  
* by Wilcoxon rank-sum test, except: † chi-square test, ‡ Fisher exact test 
§ P<0.002 (Bonferroni correction)
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Table 2. IMT of Carotid Arteries in Heterozygous Carriers of LCAT Gene Mutations and Controls  
 
 
FLD 
Carriers 
n=33 
FED 
Carriers 
n=41 
Controls 
n=280 
FED vs FLD 
Βeta (SE), P values 
FLD vs controls 
Βeta (SE), P values 
FED vs controls 
Βeta (SE), P values 
Models Models Models 
    1 2 3 1 2 3 1 2 3 
Common carotid 
IMT, mm 
0.62 
(0.55; 0.69) 
0.69 
(0.60; 0.76) 
0.65 
(0.55; 0.74) 
0.053 (0.018), 
0.003* 
0.060 (0.018), 
<0.001* 
0.030 (0.018), 
0.091 
-0.018 (0.014), 
0.201 
-0.033 (0.015), 
0.028 
-0.014 (0.015),  
0.356 
0.036 (0.013), 
0.005* 
0.026 (0.014), 
0.050 
0.016 (0.013),  
0.206 
Average 
IMT, mm 
0.59 
(0.56; 0.79) 
0.73 
(0.66; 0.88) 
0.72 
(0.62; 0.83) 
0.063 (0.017), 
<0.001* 
0.072 (0.017), 
<0.001* 
0.051 (0.017), 
0.003* 
-0.047 (0.013), 
<0.001* 
-0.063 (0.014), 
<0.001* 
-0.052 (0.015), 
<0.001* 
0.017 (0.012), 
0.172 
0.009 (0.013), 
0.504 
0.000 (0.012),  
0.975 
Maximum  
IMT, mm 
0.87 
(0.72; 1.30) 
1.24 
(0.95; 1.41) 
1.12 
(0.95; 1.45) 
0.116 (0.025), 
<0.001* 
0.122 (0.026), 
<0.001* 
0.097 (0.028), 
<0.001* 
-0.111 (0.020), 
<0.001* 
-0.115 (0.022), 
<0.001* 
-0.098 (0.024), 
<0.001* 
0.004 (0.018), 
0.809 
0.007 (0.020), 
0.726 
-0.001 (0.020),  
0.951 
Data are geometric means and (95% CI). Beta coefficient are computed on log-transformed variables. 
Model 1: adjusted for age and gender 
Model 2: as model 1 plus BMI, smoking, hypertension, family history of CVD, total cholesterol, HDL-C and triglycerides 
Model 3: as model 2 plus nationality and ultrasonographic machine  
* P<0.006 (Bonferroni correction for 9 independent comparisons) 
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Figure Legend 
Figure 1. Illustration of the likely underlying mechanism(s) leading to discrepancies in 
atherosclerosis in FLD and FED subjects 
In an attempt to explain the differences in atherosclerosis observed between FLD and FED 
subjects we depicted the relevant underlying biological mechanism(s). LCAT esterifies 
cholesterol on either HDL (α activity) or LDL (β activity). In carriers of LCAT mutations, the α 
activity (encoded by the FED allele) is compromised, but cholesteryl ester (CE) can still be 
generated on pro-atherogenic (V)LDL through normal β activity (encoded by the mutant and 
wild-type LCAT allele) (Figure 1, A). In contrast, the reduction of both α and β activity in 
carriers of FLD mutations has a larger effect on overall plasma CE and on atherogenic apoB-
containing lipoproteins compared to FED (Figure 1, B). FC free cholesterol; CE, cholesteryl 
esters. 
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SUPPLEMENTAL MATERIAL 
 
Supplemental  Table I. LCAT Mutations and Associated Biochemical Phenotype 
Sample Origin 
Amino acid 
position 
Type of 
Mutation 
Reference 
AA 
Altered 
AA 
Biochemical 
phenotype 
Genotype 
Number of 
carriers 
ITA 83 Missense Tyr stop FLD Heterozygote 1 
ITA 91 Missense Ser Pro FLD Heterozygote 1 
ITA 141 Missense Ala Thr FED Heterozygote 1 
ITA 147 Missense Arg Trp FLD Heterozygote 6 
ITA 181 Missense Ser Asn FLD Heterozygote 1 
ITA 218 Missense Lys Asn FLD Heterozygote 3 
ITA 244 Missense Arg His FED Heterozygote 4 
ITA 274 Missense Thr Ile FLD Heterozygote 5 
ITA 309 Missense Val Met FLD Heterozygote 2 
ITA 372 Missense Leu Arg FLD Heterozygote 3 
ITA stop(nt977-981) Stop / / FLD Heterozygote 2 
ITA delG, stop 16 Del, stop / / FLD Heterozygote 2 
ITA delG,Thr13--Met Del, missense / / FED Heterozygote 4 
ITA 317 Missense Val Met Unknown Heterozygote 2 
ITA 277 Missense Asp Asn Unknown Heterozygote 2 
ITA 122 Missense His Tyr Unknown Heterozygote 1 
ITA 91/141 Missense Ser/Ala Pro/Thr FED Compound Heterozygote 2 
ITA 147 Missense Arg Trp FLD Homozygote 3 
ITA 274/83 Missense/stop Thr/Tyr Ala/stop FED Compound Heterozygote 1 
ITA 218 Missense Lys Asn FLD Homozygote 3 
ITA (nt977-981)/181 Stop/missense Ser Stop/Asn FLD Compound Heterozygote 2 
ITA 372 Missense Leu Arg FLD Homozygote 2 
ITA 274 Missense Thr Ile FLD Homozygote 1 
ITA 277/317 Missense Asp/Val Asn/Met FED Compound Heterozygote 1 
NL 10 Missense Pro Gln FED Heterozygote 6 
NL 83 Stop Tyr - Term / FLD Heterozygote 4 
NL 123 Missense Thr Ile FED Heterozygote 8 
NL 131 Missense Asn Asp FED Heterozygote 17 
NL 244 Missense Arg His FED Heterozygote 1 
NL 309 Missense Val Met FLD Heterozygote 3 
NL 123 Missense Thr Ile FED Homozygote 1 
  
Supplemental Table II. Demographic, Clinical, and Lipid/Lipoprotein Data in Carriers of LCAT Gene Mutations (including 
homozygotes/compound heterozygotes) and Controls  
 
 
FLD Carriers FED Carriers Controls 
P value 
 (FED vs FLD)* 
P value 
 (FED vs controls)* 
P value 
(FLD vs controls)* 
n. 44 46 280 
 
  
Italian/Dutch 37/7 13/33 113/167 
 
  
Gender (M, %) 26 (59.1%) 31 (67.4%) 152 (54.3%) 0.41 † 0.10 † 0.55 † 
Age (y) 43.1 ±17.2 44.5 ± 15.2 43.9 ± 13.3 0.56 0.80 0.75 
BMI (kg/m
2
) 24.5 ± 4.1 25.0 ± 4.4 24.9 ± 3.9 0.48 0.48 0.63 
Smoking status 
   
0.026 ‡ 0.007 ‡ 0.237 ‡ 
Never (n, %) 27 (61.4%) 28 (62.2%) 138 (49.3%)    
Former (n, %) 12 (27.3%) 4 (8.9%) 82 (29.3%) 
 
  
Current (n, %) 5 (11.4%) 13 (28.9%) 60 (21.4%) 
 
  
Personal history of CVD (n, 
%) 
2 (4.6%) 6 (13%) 8 (2.9%) 0.26 ‡ 0.007 ‡ 0.63 ‡ 
Family history of CVD (n, %) 27 (61.4%) 24 (52.2%) 180 (64.3%) 0.38 † 0.12 † 0.71 † 
Hypertension (n, %) 13 (29.5%) 16 (34.8%) 70 (25.0%) 0.59 † 0.16 † 0.52 † 
Total Cholesterol (mg/dl) 160 ± 47 178 ± 56 200 ± 39 0.13 0.003 <0.0001§ 
LDL Cholesterol (mg/dl) 100 ± 40 119 ± 48 123 ± 35 0.08 0.38 0.001§ 
HDL Cholesterol (mg/dl) 35 ± 17 35 ± 16 58 ± 16 0.83 <0.0001§ <0.0001§ 
Triglycerides (mg/dl) 107 (85; 150) 103 (81; 149) 86 (60; 123) 0.70 0.006 0.001§ 
Non-HDL Cholesterol (mg/dl) 125 ± 45 144 ± 52 142 ± 40 0.13 0.98 0.02 
Ratio LDL-C/HDL-C 2.9 (2.1; 3.8) 3.5 (2.4; 5.0) 2.1 (1.6; 2.8) 0.08 <0.0001§ 0.002§ 
 Data are expressed as mean ± SD or as geometric mean and 95% CI or as percentage where indicated.   
* by Wilcoxon rank-sum test, except:  † chi-square test, ‡ Fisher exact test. §  P<0.002 (Bonferroni correction).  
Supplemental Table III. Demographic, Clinical, and Lipid/Lipoprotein Data in Carriers of Two Mutant LCAT Alleles and Controls 
  FLD Carriers FED Carriers Controls P value 
 (FED vs FLD)* 
P value 
 (FED vs controls)* 
P value 
(FLD vs controls)* 
n. 11 5 280 
 
  
Italian/Dutch 11/0 4/1 113/167 
 
  
Gender (M, %) 8 (72.7%) 4 (80.0%) 152 (54.3%) 1.00† 0.38† 0.36† 
Age (y) 44.2 ±26.2 37.9 ±6.3 43.9 ±13.3 0.57 0.70 0.05 
BMI (kg/m
2
) 23.3 ±3.8 24 ±3.1 24.9 ±3.9 0.43 0.57 0.14 
Smoking status 
   
0.17† 1.00† 0.04† 
Never (n, %) 4 (36.4%) 3 (60.0%) 138 (49.3%) 
 
  
Former (n, %) 7 (63.6%) 1 (20.0%) 82 (29.3%) 
 
  
Current (n, %) 0 (0%) 1 (20.0%) 60 (21.4%) 
 
  
Personal history of CVD (n, %) 0 (0%) 1 (20%) 8 (2.9%) 0.31† 0.15† 1† 
Family history of CVD (n, %) 9 (81.8%) 3 (60%) 180 (64.3%) 0.55† 1† 0.34† 
Hypertension (n, %) 4 (36.4%) 2 (40%) 70 (25%) 1.00† 0.60† 0.48† 
Total Cholesterol (mg/dl) 138 ±61 120 ±52 200 ±39 0.73 0.002 0.001 
LDL Cholesterol (mg/dl) 93 ±57 81 ±41 123 ±35 0.59 0.03 0.11 
HDL Cholesterol (mg/dl) 15 ±9 11 ±9 58 ±16 0.28 0.0001§ <0.0001§ 
Triglycerides (mg/dl) 114 (85; 328) 121 (119; 190) 86 (60; 123) 1.00 0.07 0.006 
Non-HDL Cholesterol (mg/dl) 123 ±59 110 ±52 142 ±40 0.82 0.13 0.35 
Ratio LDL-C/HDL-C 4.7 (3.4; 22.5) 6.3 (4.1; 22.2) 2.1 (1.6; 2.8) 0.89 0.0007§ 0.0001§ 
Data are expressed as mean±SD or as geometric mean and 95% CI or as percentage where indicated.  
* by Wilcoxon rank-sum test, except:  † Fisher exact test.  §  P<0.002 (Bonferroni correction).  
Supplemental Table IV. IMT of Carotid Arteries in Carriers of LCAT Gene Mutations (including homozygotes/compound heterozygotes) and 
Controls 
 
FLD 
Carriers 
n=44 
FED 
Carriers 
n=46 
Controls 
n=280 
FED vs FLD 
Βeta (SE), P values 
FLD vs controls 
Βeta (SE), P values 
FED vs controls 
Βeta (SE), P values 
Models Models Models 
    1 2 3 1 2 3 1 2 3 
Common carotid 
IMT, mm 
0.60 
(0.54; 0.69) 
0.69 
(0.59; 0.77) 
0.65 
(0.55; 0.74) 
0.049 (0.016), 
0.002§ 
0.049 (0.016), 
0.002§ 
0.023 (0.016), 
0.160 
-0.015 (0.012), 
0.220 
-0.027 (0.014), 
0.053 
-0.010 (0.014), 
0.480 
0.034 (0.012), 
0.005§ 
0.022 (0,013), 
0.110 
0.013 (0.012), 
0.310 
Average IMT, 
mm 
0.58 
(0.55; 0.77) 
0.73 
(0.64; 0.90) 
0.72 
(0.62; 0.83) 
0.062 (0.015), 
<0.001§ 
0.065 (0.015), 
<0.001§ 
0.047 (0.015), 
0.002§ 
-0.049 (0.012), 
<0.001§ 
-0.061 (0.013), 
<0.001§ 
-0.051 (0.013), 
<0.001§ 
0.014 (0.012), 
0.240 
0.004 (0.013), 
0.770 
-0.004 (0.012), 
0.730 
Maximum IMT, 
mm 
0.83 
(0.70; 0.94) 
1.20 
(0.89; 1.44) 
1.12 
(0.95; 1.45) 
0.123 (0.023), 
<0.001§ 
0.123 (0.023), 
<0.001§ 
0.100 (0.025), 
<0.001§ 
-0.127 (0.017), 
<0.001§ 
-0.124 (0.020), 
<0.001§ 
-0.108 (0.022), 
<0.001§ 
-0.004 (0.017), 
0.830 
-0.001 (0.019), 
0.970 
-0.008 (0.019), 
0.690 
Data are geometric means and (95% CI). Beta coefficient are computed on log-transformed variables. 
Model 1: adjusted for age and gender 
Model 2: as model 1 plus BMI, smoking, hypertension, family history of CVD, total cholesterol, HDL-C and triglycerides 
Model 3: as model 2 plus country and ultrasonographic machine  
§  P<0.006 (Bonferroni correction for 9 independent comparisons) 
  
  
Supplemental figure I. IMT of Carotid Arteries in Carriers of LCAT Gene Mutations and 
Controls 
Common Carotid, Average IMT and Maximum IMT values in control subjects (n=280), FED 
(n=46) and FLD (n=44) carriers. Boxes indicate the median value with the 25
th
 and 75
th
 percentiles; 
capped bars indicate the 10
th
 and 90
th
 percentiles. 
 
